FEDERAL COURT OF AUSTRALIA
Aktiebolaget Hässle v Alphapharm Pty Limited [2000] FCA 1303AKTIEBOLAGET HÄSSLE and ASTRA PHARMACEUTICALS PTY LIMITED v ALPHAPHARM PTY LIMITED
N 670 of 1999
WILCOX, MERKEL & EMMETT JJ
9 OCTOBER 2000
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N670 of 1999
BETWEEN:
AKTIEBOLAGET HÄSSLE
First AppellantASTRA PHARMACEUTICALS PTY LIMITED
Second AppellantAND:
ALPHAPHARM PTY LIMITED
RespondentJUDGES:
WILCOX, MERKEL AND EMMETT JJ
DATE:
9 OCTOBER 2000
WHERE MADE:
SYDNEY
CORRIGENDA
From the above judgment handed down in Sydney on 9 October, 2000 by Justices Wilcox, Emmett and Merkel JJ please note the following:
.at para 75, line 1, between the words “accepted” and “the proposition”, delete the word “of”;
.at para 144, line 14, replace the word “approval”, which appears in the phrase “Dr Brown’s erroneous approval”, with the word “approach”; and
.on the final page, replace the date of judgment and of certification, originally noted as 12 October 2000, with the date “9 October 2000”.
Donna Bowman
Associate for Justice WilcoxDated: 24 October 2000
FEDERAL COURT OF AUSTRALIA
Aktiebolaget Hässle v Alphapharm Pty Limited [2000] FCA 1303PATENTS - Combination patent for drug formulation – validity of patent – whether patent lacked an inventive step – whether combination obvious.
Patents Act 1990, ss 7(2), 18(1)(b)
AKTIEBOLAGET HÄSSLE and ASTRA PHARMACEUTICALS PTY LIMITED
v ALPHAPHARM PTY LIMITEDN 670 of 1999
WILCOX, MERKEL & EMMETT JJ
9 OCTOBER 2000
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 670 of 1999
BETWEEN:
AKTIEBOLAGET HÄSSLE
First AppellantASTRA PHARMACEUTICALS PTY LIMITED
(ACN 009 682 311)
Second AppellantAND:
ALPHAPHARM PTY LIMITED
(ACN 002 359 739)
RespondentJUDGES:
WILCOX, MERKEL AND EMMETT JJ
DATE OF ORDER:
9 OCTOBER 2000
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The appeal be dismissed.
2.The appellants, Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited, pay the costs of the respondent, Alphapharm Pty Limited.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 670 of 1999
BETWEEN:
AKTIEBOLAGET HÄSSLE
First AppellantASTRA PHARMACEUTICALS PTY LIMITED
Second AppellantAND:
ALPHAPHARM PTY LIMITED
Respondent
JUDGES:
WILCOX, MERKEL AND EMMETT JJ
DATE:
9 OCTOBER 2000
PLACE:
SYDNEY
REASONS FOR JUDGMENT
EMMETT J:
The Court: The first appellant, Aktiebolaget Hässle, a Swedish corporation, is registered as the patentee of Australian Patent Number 601974 (“the Formulation Patent”). The second appellant, Astra Pharmaceuticals Pty Limited, an Australian company, is related to the first appellant and
isthe exclusive licensee in Australia of the Formulation Patent.in Australia.Both appellants are members of the Astra pharmaceuticals group whose head office is in Sweden. As nothing turns on the identity of particular companies in the group, itItis convenient to refer to both appellants, andtothe group to which they belong, as “Astra”. The respondent, Alphapharm Pty Limited (“Alphapharm”), is an Australian company that…
Keep reading for free
Create a free CaseChat account to read Aktiebolaget Hässle v Alphapharm Pty Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2000] FCA 1303
- Decision Date
CaseChat Overview and Summary
The Court of Appeal addressed the key legal issue of whether the claimed formulation involved an inventive step. The Court noted that for a patent to be valid, it must involve some degree of inventiveness, but this could be small. The Court applied the test of whether the invention would have been obvious to a non-inventive skilled worker in the field, equipped with the common general knowledge as at the priority date. The Court held that while the use of an enteric coating and the core material comprising omeprazole and an alkaline reacting compound or salt were obvious, the use of a subcoating layer was not. The Court found that the evidence showed that it was not obvious to those in the field that such a subcoating layer would be effective or necessary. The Court rejected the argument that the combination of the claimed elements was obvious from the outset.
The Court of Appeal held that the patent was valid as it involved an inventive step in the use of a subcoating layer within the formulation described in the patent. The Court held that the appeal should be dismissed and that the appellants should pay the costs of the respondent. The Court found that the claimed formulation did not involve an inventive step as a whole, but that the use of the subcoating layer was not obvious and thus contributed to the inventiveness of the formulation. The Court rejected the argument that the finding of the primary judge that the combination claimed in the patent was not obvious at the outset logically concluded the issue of obviousness in favour of the appellants.
Orders
Orders of the court
1. The appeal be dismissed.
2. The appellants, Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited, pay the costs of the respondent, Alphapharm Pty Limited.
Background
Background to the litigation
The matter initially came before Lehane J in the Federal Court of Australia, who found that the patents were obvious and lacked an inventive step. The appellants then appealed to the Full Court of the Federal Court, arguing that the primary judge erred in finding that the invention was obvious. The Full Court considered the evidence and arguments presented by both parties and reviewed the relevant legal principles.
Evidence
Evidence Before The Court
Decision
Reasons for decision
1. Was it obvious for the hypothetical formulator to try out the idea of a subcoat in the pharmaceutical formulation?
2. Was it obvious for the hypothetical formulator to try out a subcoat falling within the description contained in the patent?
3. Are Claims 13, 14, 15, 16, and 17 entirely dependent on Claim 1 for the purposes of considering the question of inventive step?
Held
1. It was not obvious for the hypothetical formulator to try out the idea of a subcoat in the pharmaceutical formulation, as it was uncertain whether such a subcoat would be beneficial or even necessary.
2. It was obvious for the hypothetical formulator to try out a subcoat falling within the description contained in the patent, as it was within the realm of possibilities worth exploring.
3. Claims 13, 14, 15, 16, and 17 are not entirely dependent on Claim 1 for the purposes of considering the question of inventive step, as no distinction was suggested between Claim 1 and the other claims.
Ratio Decidendi
Legal Principle Established
Claims 13, 14 and 15 are concerned with the preparation of an oral formulation. Claims 16 and 17 are concerned with methods in “the treatment of gastrointestinal disease”. Although Claims 13, 15, 16 and 17 are not, in terms, entirely dependent on Claim 1, there has been no suggestion that any distinction should be drawn between Claim 1 and any of the other claims for the purposes of considering the question of inventive step. Accordingly, it is not necessary at this stage to deal with the detail of any of those other claims. Tthe law as to “inventive step” The inventive element needed to sustain a patent may be small. A “scintilla of inventiveness” is sufficient; “no smallness or simplicity will prevent a patent being good”: see – Meyers Taylor Pty Ltd v Vicarr Industries Ltd (1977) 137 CLR 228 at 249. However, while While a simple idea may be inventive, it is nevertheless essential for the validity of a patent that there be some inventiveness. In Allsop Inc v Bintang Ltd (1989) 15 IPR 686 at 701, a Full Court of this Court adopted a statement made in the Supreme Court of the United States in Graham v John Deere Co of Kansas City (1966) 383 US 1 at 15: “the subject matter sought to be patented must be beyond the skill of the calling”. The Full Court also referred to a dictum of Cotton LJ in Britain v Hirsch (1888) 5 RPC 226:“I do not agree with the view … that when anything is done which has not been done before, that is sufficient to justify a patent being obtained for it. In my opinion, it must be a question of whether there is sufficient invention to justify a monopoly being granted by the Crown in the particular thing.” Section 100(1)(e) of the 1952 Act speaks of a patent being revoked where the invention is obvious and does not involve an inventive step “having regard to what was known or used in Australia” on or before the relevant priority date”. That which is obvious does not involve an inventive step. That which involves an inventive step is not obvious. That matter is to be judged against the background of what was known or used in Australia on or before the relevant priority date. The expression “what was known or used in Australia on or before the priority date” has been explained by reference to a line of authority that predated the 1952 Act. The test of what was obvious, and did not involve an inventive step, having regard to what was known or used in Australia at the priority date, isof whether the invention would have been obvious to a non-inventive skilled worker in the field, equipped with the common general knowledge in that particular field of endeavour as at the priority date. It cannot be assumed that common general knowledge in Australia is the same as common general knowledge in a place outside Australia. Itt is necessary to prove, by evidence in the particular case, in any case just what constitutes the state ofrelevant common general knowledge in Australia: see is Wellcome Foundation Ltd v V.R. Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 at 270.34 Common general knowledge comprises that which is known to, or used by, those in the relevant field. Common general knowledge consists of the background knowledge and experience that is available to all (not merely particular individuals) in the relevant field, in considering the making of new products or improvements in old products. It must be treated as being used by an individual as a general body of knowledge: see – Minnesota Mining &and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253 at 292. The issue in the present case